The DPP4 Inhibitor Linagliptin Protects from Experimental Diabetic Retinopathy.

The DPP4 Inhibitor Linagliptin Protects from Experimental Diabetic Retinopathy.

Dipeptidyl peptidase 4 (DPP4) inhibitors improve glycemic control in type 2 diabetes, however, their influence on the retinal neurovascular unit remains unclear.Vasculo- and neuroprotective effects were assessed in experimental diabetic retinopathy and high glucose-cultivated C. elegans, respectivel...

Full description

Bibliographic Details
Main Authors: Nadine Dietrich, Matthias Kolibabka, Stephanie Busch, Petra Bugert, Ulrike Kaiser, Jihong Lin, Thomas Fleming, Michael Morcos, Thomas Klein, Andrea Schlotterer, Hans-Peter Hammes
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2016-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC5152931?pdf=render

Internet

http://europepmc.org/articles/PMC5152931?pdf=render

Similar Items